Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR

Hepatology

Volumn 57, Issue 1, 2013, Pages 120-130

  Keng, Vincent W ^a,b,h   Sia, Daniela ^a,c   Sarver, Aaron L ^a,d   Tschida, Barbara R ^a,b   Fan, Danhua ^a,d   Alsinet, Clara ^a   Solé, Manel ^a   Lee, Wai L ^a   Kuka, Timothy P ^a   Moriarity, Branden S ^a,b   Villanueva, Augusto ^a   Dupuy, Adam J ^e   Riordan, Jesse D ^e   Bell, Jason B ^a,b   T Silverstein, Kevin A ^a,d   Llovet, Josep M ^a,f,g   Largaespada, David A ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^h HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING PROTEIN 42; ADENOSINE KINASE; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; NUCLEAR FACTOR I; PARTITIONING DEFECTIVE PROTEIN 3; PROTEIN; SOLUTE CARRIER FAMILY 25 MEMBER 13; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHROMOSOME 7; FEMALE; GENE EXPRESSION; GENE LOCUS; GENOTYPE; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSPOSON;

ANIMALS; BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 7; DNA TRANSPOSABLE ELEMENTS; FEMALE; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; MUTAGENESIS, INSERTIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEX FACTORS;

EID: 84872157669     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26004     Document Type: Article

References (32)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
3. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-124.
4. Dupuy AJ, Rogers LM, Kim J, Nannapaneni K, Starr TK, Liu P, et al. A modified sleeping beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res 2009; 69: 8150-8156.
5. Keng VW, Villanueva A, Chiang DY, Dupuy AJ, Ryan BJ, Matise I, et al. A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol 2009; 27: 264-274.
6. Starr TK, Allaei R, Silverstein KA, Staggs RA, Sarver AL, Bergemann TL, et al. A transposon-based genetic screen in mice identifies genes altered in colorectal cancer. Science 2009; 323: 1747-1750.
7. de Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J, et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A 2002; 99: 2948-2953.
8. Sarver AL, Erdman J, Starr T, Largaespada DA, Silverstein KA. TAPDANCE: An Automated tool to identify and annotate Transposon insertion CISs and associations between CISs from next generation sequence data. BMC Bioinformatics 2012;13:154.
9. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68: 6779-6788.
10. Keng VW, Tschida BR, Bell JB, Largaespada DA. Modeling hepatitis B virus X-induced hepatocellular carcinoma in mice with the Sleeping Beauty transposon system. HEPATOLOGY 2011; 53: 781-790.
11. Wangensteen KJ, Wilber A, Keng VW, He Z, Matise I, Wangensteen L, et al. A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver. HEPATOLOGY 2008; 47: 1714-1724.
12. Bell JB, Podetz-Pedersen KM, Aronovich EL, Belur LR, McIvor RS, Hackett PB. Preferential delivery of the Sleeping Beauty transposon system to livers of mice by hydrodynamic injection. Nat Protoc 2007; 2: 3153-3165.
13. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37(Suppl. 4): S3-S8.
14. Chang CM, Shu HK, Ravi L, Pelley RJ, Shu H, Kung HJ. A minor tyrosine phosphorylation site located within the CAIN domain plays a critical role in regulating tissue-specific transformation by erbB kinase. J Virol 1995; 69: 1172-1180.
15. Landau M, Fleishman SJ, Ben-Tal N. A putative mechanism for downregulation of the catalytic activity of the EGF receptor via direct contact between its kinase and C-terminal domains. Structure 2004; 12: 2265-2275.
16. Boerner JL, Danielsen A, Maihle NJ. Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp Cell Res 2003; 284: 111-121.
17. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60: 1383-1387.
18. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007; 27: 55-76.
19. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-1983.
20. Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. Am J Clin Pathol 2008; 129: 245-251.
21. Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S, et al. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res 2008; 68: 3037-3042.
22. Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. HEPATOLOGY 2007; 45: 1298-1305.
23. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. HEPATOLOGY 2007; 45: 42-52.
24. Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012; 148: 72-83.
25. Ho Sui SJ, Fulton DL, Arenillas DJ, Kwon AT, Wasserman WW. oPOSSUM: integrated tools for analysis of regulatory motif over-representation. Nucleic Acids Res 2007; 35: W245-252.
26. Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, Kennedy BP, et al. oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res 2005; 33: 3154-3164.
27. Xie Z, Zhang H, Tsai W, Zhang Y, Du Y, Zhong J, et al. Zinc finger protein ZBTB20 is a key repressor of alpha-fetoprotein gene transcription in liver. Proc Natl Acad Sci U S A 2008; 105: 10859-10864.
28. Wang Q, Tan YX, Ren YB, Dong LW, Xie ZF, Tang L, et al. Zinc finger protein ZBTB20 expression is increased in hepatocellular carcinoma and associated with poor prognosis. BMC Cancer 2011; 11: 271.
29. Chang KW, Chen HL, Chien YH, Chen TC, Yeh CT. SLC25A13 gene mutations in Taiwanese patients with non-viral hepatocellular carcinoma. Mol Genet Metab 2011; 103: 293-296.
30. Guo H, Liu H, Mitchelson K, Rao H, Luo M, Xie L, et al. MicroRNAs-372/373 promote the expression of hepatitis B virus through the targeting of nuclear factor I/B. HEPATOLOGY 2011.
31. Boison D, Scheurer L, Zumsteg V, Rulicke T, Litynski P, Fowler B, et al. Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proc Natl Acad Sci U S A 2002; 99: 6985-6990.
32. Bjursell MK, Blom HJ, Cayuela JA, Engvall ML, Lesko N, Balasubramaniam S, et al. Adenosine kinase deficiency disrupts the methionine cycle and causes hypermethioninemia, encephalopathy, and abnormal liver function. Am J Hum Genet 2011; 89: 507-515.